Epistra Inc. (Headquarters: Tokyo, CEO: Yosuke Ozawa) participated in the “Laboratory Automation Monthly Study Group” hosted by the Laboratory Automation Research Group on November 18, 2025, where CTO Taku Tsuzuki gave a presentation.
The study group was held on November 18, 2025, at the Shimadzu Corporation Tokyo Innovation Plaza, with both in-person and online attendance options.
About the Laboratory Automation Monthly Study Group
This monthly study group is a community that brings together developers, engineers, and researchers working on research automation across organizational boundaries. Discussions cover hardware, software, operational management, and domain-specific challenges. The group features short talks, information exchange, and networking among experts from diverse fields including life sciences, chemistry, materials science, robotics, and IT.
Presentation Topic
“Adaptive Experimental Design in Life Sciences — An Overview of Published Case Studies, Epistra’s Approach, and Future Prospects”
Related Articles
- Epistra Contributes Article on "AI-Robot-Driven Drug Development" to Pharmacia, Journal of the Pharmaceutical Society of JapanEpistra CTO Taku Tsuzuki and CEO Yosuke Ozawa contributed an article on AI-robot-driven drug development to Pharmacia, Vol. 62 No. 7, published by the Pharmaceutical Society of Japan.
- Cell Culture Optimization Software 'CellTune Ver.2' Launches GloballyEpistra Inc. announces the global launch of 'CellTune Ver.2,' the updated version of the co-developed cell culture optimization software with Shimadzu Corporation, on June 29, 2026. The new version introduces cloud-based subscription delivery and overseas expansion of custom media manufacturing services.
- Speaking Engagement: CEO Yosuke Ozawa Presented at the 10th Shonan iPark Regenerative Medicine SeminarOn June 3, 2026, Epistra Inc. CEO Yosuke Ozawa presented at the 10th Shonan iPark Regenerative Medicine Seminar, sharing implementation case studies and future prospects for AI and mathematical optimization in regenerative medicine process development.